In a landmark development for personalized medicine, Moderna, Inc. and Merck (known as MSD outside the U.S. and Canada) announced today that their investigational mRNA-based cancer vaccine, in combination with the immunotherapy Keytruda, has demonstrated a sustained and significant improvement in long-term survival for patients with high-risk melanoma.
New data from a median five-year follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study revealed that the combination therapy reduced the risk of recurrence or death by 49% (HR=0.510) compared to Keytruda alone. The findings represent a major milestone in oncology, suggesting that the benefits of individualized neoantigen therapy (INT) are not only immediate but also durable over half a decade.
Sustained Success in High-Risk Patients
The study focused on patients with Stage III/IV melanoma who had undergone complete surgical resection but remained at high risk for the cancer’s return. While Keytruda (pembrolizumab) is already a standard of care in this setting, the addition of intismeran autogene (also known as mRNA-4157 or V940) appears to significantly bolster the immune system’s long-term vigilance.
How the “Cancer Vaccine” Works
Unlike traditional vaccines that prevent infection, Intismeran autogene is a therapeutic “individualized neoantigen therapy.” Each dose is custom-built for the specific patient.
The process involves:
- Sequencing: Analyzing the DNA of a patient’s unique tumor.
- Identification: Using an algorithm to identify up to 34 neoantigens (mutations) specific to that patient’s cancer.
- Creation: Developing a synthetic mRNA strand that teaches the patient’s own immune system to recognize and attack cells carrying those specific mutations.
When paired with Keytruda, which “unmasks” cancer cells so the immune system can see them, the vaccine provides a targeted “instruction manual” for the T-cells to finish the job.
Expanding the Horizon
The success in melanoma has paved the way for a massive clinical expansion. Merck and Moderna confirmed that their Phase 3 INTerpath-001 trial for adjuvant melanoma is now fully enrolled.
Furthermore, the companies are aggressively testing the combination across other difficult-to-treat cancers, including:
- Non-Small Cell Lung Cancer (NSCLC): Two Phase 3 studies are currently enrolling.
- Bladder Cancer: Multiple Phase 2 studies for muscle-invasive and non-muscle-invasive types.
- Renal Cell Carcinoma (Kidney Cancer): A Phase 2 study is fully enrolled.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Safety and Next Steps
The companies reported that the safety profile of the combination therapy remains consistent with earlier data, with no new major safety signals emerging at the five-year mark. Detailed results from this follow-up analysis are expected to be presented at an upcoming medical conference.
Last Modified:
